Researchers reconstituted capsids from Cowpea Chlorotic Mottle Virus (CCMV) to form virus-like particles (VLPs) that encapsulate heterologous nucleic acids. The reported cargoes were a 3,690 bp plasmid (pVax-GFP) and a 1,168 nt GFP-mRNA. VLPs containing the plasmid remained structurally stable for up to five weeks when stored in buffer at pH 7.2 and at pH 5, the authors reported. By contrast, VLPs with mRNA showed stability only when kept at pH 4.5, and only for a shorter interval—up to three weeks. The abstract did not list the specific assembly protocols, molar ratios of capsid protein to nucleic acid, or detailed storage formulations; those methodological specifics were not reported in the source abstract.
The distinct pH-dependent stability profiles suggest differential interactions between capsid proteins and nucleic-acid types. Short storage times for mRNA at low pH imply a narrower handling window for RNA-loaded VLPs compared with plasmid-loaded particles. The authors reported these stability endpoints but did not provide further quantitative stability metrics in the abstract.
When VLPs were added directly to culture medium, cell lines of both fish and mammalian origin readily internalised the particles, the study team observed. Uptake occurred without apparent discrimination between fish and mammalian cells. However, internalisation did not equal functional delivery: data indicated that VLPs in the medium failed to unpack and release their nucleic-acid cargoes to permit reporter-gene expression in either cell type under those conditions.
This separation of physical uptake and functional gene transfer is important. The VLP shell reached the intracellular compartment but retained the payload, meaning reporter expression was absent after simple incubation. The abstract did not provide microscopy time courses, endosomal localization markers, or quantitative counts of internalised VLPs, so the precise intracellular fate beyond the broad observation was not reported in the source abstract.
The authors tested approaches to overcome the apparent block in unpacking. They reported that when VLPs were delivered to cells via transfection reagents, nucleic acids were transferred and reporter gene expression followed. In other words, forced entry through chemical transfection enabled the payload to reach a bioavailable compartment and be expressed. The abstract did not supply which transfection reagents were used, nor detailed efficiency metrics.
The team also co-administered VLPs with the cell-penetrating peptide dfTAT. In that experiment, only VLPs containing pVax-GFP assembled at pH 7.2 were able to transfer DNA to mammalian cells; fish cells remained refractory and did not show reporter expression under the dfTAT conditions reported. Thus, dfTAT altered outcomes in a host-dependent manner. The abstract does not include dose ranges for dfTAT, incubation times, or mechanistic readouts such as endosomal escape assays—those methodological details were not reported in the source abstract.
These findings separate two operational modes: passive addition to medium (internalisation without unpacking) and assisted entry (transfection or peptide-mediated) that permits payload release and expression, at least in mammalian lines. Fish cells appeared less permissive to peptide-mediated unpacking in vitro under the reported conditions.
The authors moved to in vivo models to test functional delivery. They injected pVax-GFP–containing VLPs intramuscularly into zebrafish larvae and juveniles and examined myocytes for plasmid uptake and reporter expression. The abstract reports that VLP-delivered plasmid DNA produced transfer to myocytes with an efficiency described as comparable to injections of naked plasmid DNA.
This in vivo result contrasts with the in vitro outcome in fish cell cultures, where unpacking and reporter expression were limited without transfection aids. In muscle tissue, mechanical and biological differences—such as direct cytoplasmic access after injection or local tissue processes—may permit VLPs to release plasmid DNA. The abstract does not provide time points post-injection, numbers of animals, quantitative expression levels, or histological details; those experimental specifics were not reported in the source abstract.
The manuscript is a preprint and has not been peer reviewed, which the authors stated. The abstract provides clear qualitative endpoints—stability windows by pH, in vitro uptake without unpacking, facilitation of delivery by transfection or dfTAT in mammalian cells, and successful intramuscular plasmid transfer in zebrafish—but it omits many operational details. Critical parameters such as particle-to-cell ratios, concentrations used for dfTAT, identities of mammalian and fish cell lines, quantitative transfection efficiencies, and temporal kinetics were not reported in the abstract. Those gaps limit immediate interpretation of scalability, reproducibility, and safety.
Future experimental descriptions in the full manuscript or subsequent peer-reviewed publication should provide those methodological details and quantitative readouts. For now, the reported data form a coherent set of observations: CCMV VLPs can encapsulate either plasmid DNA or mRNA; storage stability depends on cargo and pH; VLPs are internalised by fish and mammalian cells but frequently fail to unpack in fish cell culture without auxiliary agents; and direct intramuscular administration into zebrafish enabled plasmid transfer to myocytes at levels comparable to naked DNA injection, according to the authors.
The work establishes an experimental foundation rather than clinical readiness, and the absence of peer review and full-method disclosure in the abstract are the principal limitations reported in the source.